Study of genetic polymorphisms in the tumor necrosis factor α promoter region in Spanish patients with psoriasis;Estudio de los polimorfismos genéticos de la región promotora del TNF-α en pacientes Españoles afectos de psoriasis

Actas Dermo-Sifiliograficas

Volumn 103, Issue 4, 2012, Pages 301-307

  Gallo, E ^a   Cabaleiro, T ^a   Roman M ^a   Abad Santos, F ^a   Dauden E ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Polymorphisms; Psoriasis; Tumor necrosis factor

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PSORIASIS;

EID: 84859949600     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.adengl.2012.05.009     Document Type: Article

References (42)

1. Daudén E. Farmacogenética I. Concepto, historia, objetivos y áreas de estudio. Actas Demosifiliogr. 2006;97:623-6.
2. Kalow W, Tang BK, Endrenyi I. Hypothesis: comparison of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8:283-9. (Pubitemid 28372321)
3. Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol. 2007;25:563-7. (Pubitemid 350087603)
4. Höhler T, Kruger A, Schneider PM, Schopf RE, Knop J, Rittner C, et al. A TNF-alpha promoter polymorphism is associated with juvenile onset psoriasis and psoriatic arthritis. J Invest Dermatol. 1997;109:562-5.
5. Reich K, Westphal G, Schulz T, Müller M, Zipprich S, Fuchs T, et al. Combined analysis of polymorphisms of the tumor necrosis factor-alpha and interleukin-10 promoter regions and polymorphic xenobiotic metabolizing enzymes in psoriasis. J Invest Dermatol. 1999;113:214-20. (Pubitemid 30202525)
6. Reich K, Mössner R, König IR, Westphal G, Ziegler A, Neumann C. Promoter polymorphisms of the genes encoding tumor necrosis factor-alpha and interleukin-1beta are associated with different subtypes of psoriasis characterized by early and late disease onset. J Invest Dermatol. 2002;118:155-63. (Pubitemid 34107437)
7. Nishibu A, Oyama N, Nakamura K, Kaneko F. Lack of association of TNF-238A and -308A in Japanese patients with psoriasis vulgaris, psoriatic arthritis and generalized pustular psoriasis. J Dermatol Sci. 2002;29:181-4. (Pubitemid 35375273)
8. Nedoszytko B, Szczerkowska-Dobosz A, Zabłotna M, Gleń J, Rebała K, Roszkiewicz J. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population. Br J Dermatol. 2007;157:165-7. (Pubitemid 46934284)
9. Reich K, Hüffmeier U, König IR, Lascorz J, Lohmann J, Wendler J, et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*- 857 independent of the PSORS1 risk allele. Arthritis Rheum. 2007;56:2056-64. (Pubitemid 47110405)
10. Baran W, Szepietowski JC, Mazur G, Baran E. A - 308 promoter polymorphism of tumor necrosis factor alpha gene does not associate with the susceptibility to psoriasis vulgaris. No difference either between psoriasis type I and type II patients. Acta Dermatovenerol Alp Panonica Adriat. 2006;15:113-8. (Pubitemid 44546082)
11. Kingo K, Kõks S, Silm H, Vasar E. IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun. 2003;4:455-7. (Pubitemid 38967611)
12. Baran W, Szepietowski JC, Mazur G, Baran E. IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm Venereol. 2008;88:113-6. (Pubitemid 351507179)
13. Nair RP, Ruether A, Stuart PE, Jenisch S, Tejasvi T, Hiremagalore R, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128:1653-61. (Pubitemid 351847381)
14. Duffin KC, Krueger GG. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J Invest Dermatol. 2009;129:827-33.
15. Gudjonsson JE. Genetic variation and psoriasis. G Ital Dermatol Venereol. 2008;143:299-305.
16. Baran W, Szepietowski JC, Mazur G, Baran E. TGF-beta(1) gene polymorphism in psoriasis vulgaris. Cytokine. 2007;38:8-11. (Pubitemid 46990920)
17. Baran W, Szepietowski JC, Mazur G, Baran E. IFN-gamma promoter gene polymorphism in psoriasis vulgaris. Biomarkers. 2008;13:52-8.
18. Tansey MG, Szymkowski DE. The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today. 2009;14:1082-8.
19. Gottlieb AB. Tumor necrosis factor blockade: mechanism of action. J Investig Dermatol Symp Proc. 2007;12:1-4. (Pubitemid 46763026)
20. Kohno T, Tam LT, Stevens SR, Louie JS. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs antitumor necrosis factor mAbs. J Investig Dermatol Symp Proc. 2007;12:5-8. (Pubitemid 46763031)
21. Rácz E, Prens EP. Molecular pathophysiology of psoriasis and molecular targets of antipsoriatic therapy. Expert Rev Mol Med. 2009;11:1-18.
22. Llanos C, Soto L, Sabugo F, Bastías MJ, Salazar L, Aguillón J, et al. Papel de los polimorfismos -238 y -308 del promotor del factor de necrosis tumoral alfa en la patogenia y respuesta a tratamiento anti- factor de necrosis tumoral alfa en artritis reumatoide. Rev Méd Chile. 2005;133:1089-95.
23. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum. 2003;48:1849-52. (Pubitemid 36828679)
24. Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. Scand J Rheumatol. 2004;33:228-32. (Pubitemid 39180165)
25. Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. Scand J Rheumatol. 2006;35:435-40. (Pubitemid 47215721)
26. Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum. 2007;57:1426-30. (Pubitemid 350308840)
27. Seitz M, Wirthmüller U, Möller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford). 2007;46:93-6. (Pubitemid 44932793)
28. Rahman P, O'Rielly DD. Psoriatic arthritis: genetic susceptibility and pharmacogenetics. Pharmacogenomics. 2008;9:195-205. (Pubitemid 351566943)
29. Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. Ann Rheum Dis. 2008;67:478-84. (Pubitemid 351498427)
30. Kang CP, Lee KW, Yoo DH, Kang C, Bae SC. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford). 2005;44:547-52. (Pubitemid 41511149)
31. Coenen MJ, Toonen EJ, Scheffer H, Radstake TR, Barrera P, Franke B. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics. 2007;8:761-73. (Pubitemid 47288976)
32. Oregón-Romero E, Vázquez-Del Mercado M, Ruiz-Quezada SL, Navarro-Hernández RE, Rangel-Villalobos H, Martínez-Bonilla G, et al. Tumor necrosis factor α-308 and -238 polymorphisms in rheumatoid arthritis. Association with messenger RNA expression and sTNF-α. J Invest Med. 2008;56:937-43.
33. Mössner R, Kingo K, Kleensang A. Association of TNF-238 and-308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthitis but not with pustulosis palmoplantaris. J Invest Dermatol. 2005;124:282-4. (Pubitemid 40100984)
34. Magalhaes RF, Biral AC, Pancoto JA, Donadi AE, Mendes CT, Magna LA, et al. Human leukocyte antigen (HLA) and single nucleotide polymorphisms (SNPs) tumor necrosis factor (TNF)- alpha and -308 as genetic markers of susceptibilitiy to psoriasis and severity of the disease in a long-term follow-up Brazilians. Int J Dermatol. 2010;49:1133-40.
35. Kim TG, Pyo CW, Hur SS, Kim YK, Hwang HY, Youn JI, et al. Polymorphisms of tumor necrosis factor (TNF) α and βgenes in Korean patients with psoriasis. Arch Dermatol Res. 2003;295:8-13.
36. Tsunemi Y, Nishibu A, Saeki H, Oyama N, Nakamura K, Kishimoto M, et al. Lack of association between the promoter polymorphisms at positions -308 and -238 of the tumor necrosis factor alpha gene and psoriasis vulgaris in Japanese patients. Dermatology. 2003;207:371-4. (Pubitemid 37505785)
37. Settin A, Hassan H, El-Baz R, Hassan T. Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt. Acta Dermatoven APA. 2009;18:105-12.
38. Craven N, Jackson C, Kirby B. Cytokine gene polymorphism in psoriasis. Br J Dermatol. 2001;144:849-53.
39. Li C, Wang G, Gao Y, Liu L, Gao T. TNF-alpha gene promoter -238G > A and -308G > A polymorphisms alter risk of psoriasis vulgaris: a meta-analysis. J Invest Dermatol. 2007;127:1886-92. (Pubitemid 47075376)
40. Rahman P, Siannis F, Butt C, Farewell V, Peddle L, Pellett F, et al. TNFα polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis. 2006;65:919-23.
41. Oestreicher JL, Walters IB, Kikuchi T, Gilleaudeau P, Surette J, Schwertschlag U, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J. 2001;1:272-87. (Pubitemid 33756652)
42. Daudén E. Farmacogenética II. Métodos moleculares de estudio, bioinformática y aspectos éticos. Actas Dermosifiliogr. 2007;98:3-13.